School of Medicine
Showing 531-540 of 564 Results
-
Aileen Whyte
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
BioDr. Aileen Whyte, a licensed psychologist in California, brings over two decades of specialized expertise to the treatment of eating disorders in young people. Beyond her clinical practice, Dr. Whyte actively works on implementing strategies to expand the reach of evidence-based treatments for eating disorders, aiming to make these best-practice interventions more accessible to a wider population.
Dr Whyte serves as the Director of the Stanford Outpatient Child & Adolescent Eating Disorders Clinic, where she provides treatment to young people with eating disorders and provides supervision to psychology and psychiatry fellows. Dr Whyte is a certified practitioner and consultant in Family-Based Treatment (FBT) for eating disorders. She serves as a study therapist in NIMH-sponsored randomized clinical trials focused on examining FBT and related adaptations.
In addition to her clinical responsibilities, Dr. Whyte has led multiple seminars, workshops, and training sessions dedicated to the treatment of eating disorders. She provides ongoing training and consultation in FBT, reaching diverse audiences, including multidisciplinary clinicians, psychologists, and psychiatrists, within the US and internationally.
Dr. Whyte earned her PhD in Clinical Psychology from the New School for Social Research in New York. Her research and clinical interests converge on the implementation and dissemination of evidence-based treatments for eating disorders. -
Leanne Williams
Vincent V.C. Woo Professor, Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator) and, by courtesy, of Psychology
Current Research and Scholarly InterestsA revolution is under way in psychiatry. We can now understand mental illness as an expression of underlying brain circuit disruptions, shaped by experience and genetics. Our lab is defining precision brain circuit biotypes for depression, anxiety and related disorders. We integrate large amounts of brain imaging, behavioral and clinical data and computational approaches. Biotypes are used in personalized intervention studies with selective drugs, neuromodulation and exploratory therapeutics.
-
Nolan Williams
Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator) and, by courtesy, of Radiology (Neuroimaging and Neurointervention)
BioNolan Williams, M.D. is an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. The long-term goals of his research program are to develop innovative technologies and therapeutics capable of modulating the neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team has been developing neuroimaging-based approaches to precisely target therapeutic delivery and predict treatment responses to therapeutic neuromodulation and psychedelics. Dr. Williams earned his M.D. and completed his dual residencies in neurology and psychiatry at the Medical University of South Carolina (MUSC). Triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry, Dr. Williams brings a comprehensive background in clinical neuroscience to his role as a clinically active neuropsychiatrist. His expertise extends to the development and implementation of novel therapeutics, including devices and novel compounds, for central nervous system illnesses.
Over the past decade, Dr. Williams’ laboratory alongside collaborators at Stanford University have pioneered multiple novel therapeutic and human neuroscience approaches. Notably, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. SAINT received FDA Breakthrough Device Designation Status (2021) and FDA Clearance (2022) and is the first psychiatric treatment to be covered by Medicare New Technology Add-On Payment (NTAP). As of April 2024, SAINT has been reimbursed for patients suffering from severe depression within inpatient psychiatric units. The SAINT technology is being deployed both clinically and in research protocols in laboratories and hospitals worldwide. Dr. Williams also has an expertise in psychedelic medicines for neuropsychiatric illness and is the first investigator to conduct mechanistic clinical trials exploring the neurobiological effects of ibogaine.
His research accomplishments have garnered international recognition, earning prestigious awards from the Pritzker Neuropsychiatric Disorders Consortium, One Mind Institute, Wellcome Leap Foundation, International Brain Stimulation Conference, National Institute of Mental Health (Biobehavioral Research Award for Innovative New Scientists), Society of Biological Psychiatry (A. E. Bennett Award), along with multiple awards from the Brain Behavior Research Foundation (most notably the Gerald L. Klerman Award). His work has been featured in Scientific American, The New York Times, The Washington Post, USA Today, CBS Sunday Morning, and the TODAY Show. -
Sharon E. Williams PhD
Clinical Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
Current Research and Scholarly InterestsDr. WilliamsÂ’ work focuses primarily on cognitive and emotional recovery of children who have been medically compromised. With improved medical treatment and increased survival rates comes the need to better understand the challenges that patients face following a life threatening illness or injury. Dr. Williams utilizes neuropsychological assessments to understand the cognitive abilities of children who have been diagnosed with cancer, head injuries, genetic disorders and other medical conditions.
-
Helen Wilson
Clinical Professor, Psychiatry and Behavioral Sciences
BioDr. Wilson is a licensed clinical psychologist with expertise on the effects of trauma across the lifespan. She provides clinical services for children, adolescents, adults, and families affected by trauma and other forms of anxiety and stress. Dr. Wilson also leads an active research program focused on relationships between childhood trauma and health risk behavior in adolescence and adulthood. She is the Principal Investigator of GIRLTALK: We Talk, a longitudinal study funded by the National Institute of Child Health and Human Development (NICHD) that examines links from childhood violence exposure to dating violence and sexual risk in young women from low-income communities in Chicago. Dr. Wilson has authored or co-authored thirty journal articles and book chapters related to these topics, and she regularly presents her work at local and national conferences. She is on the editorial board of the Journal of Youth and Adolescence.
-
Shannon Wiltsey Stirman
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Current Research and Scholarly InterestsThe overarching goal of my program of research is to determine how to facilitate access to evidence-based psychosocial interventions (EBPs) in community and public sector mental health settings. Areas of emphasis include training and consultation, treatment fidelity and adaptation, AI and digital mental health interventions, and the identification of strategies that promote sustained implementation of EBPs.
